ICON plc: Commencement of Share Repurchase Programme Read more about ICON plc: Commencement of Share Repurchase Programme
ICON Names New Global Head of Clinical Research Services Read more about ICON Names New Global Head of Clinical Research Services
ICON Reports Q3 revenue growth of 7% to $241 million and net new business of $431 million. (NASDAQ:ICLR) (ISIN:IE0005711209) Read more about ICON Reports Q3 revenue growth of 7% to $241 million and net new business of $431 million. (NASDAQ:ICLR) (ISIN:IE0005711209)
ICON Announces Peter Gray To Retire As CEO Read more about ICON Announces Peter Gray To Retire As CEO
ICON Selected as a Preferred Provider for Early Phase Clinical Development by Bristol-Myers Squibb Read more about ICON Selected as a Preferred Provider for Early Phase Clinical Development by Bristol-Myers Squibb
ICON Reports Second Quarter 2011 Net New Business of $310 million, Revenue of $233 million and EPS of 21c (NASDAQ:ICLR) (ISIN:IE0005711209) Read more about ICON Reports Second Quarter 2011 Net New Business of $310 million, Revenue of $233 million and EPS of 21c (NASDAQ:ICLR) (ISIN:IE0005711209)
ICON Shareholders Vote in Favour of All Resolutions at Its Annual General Meeting Read more about ICON Shareholders Vote in Favour of All Resolutions at Its Annual General Meeting
ICON Selected by Pfizer as a Global Strategic Partner for Clinical Research and Development Read more about ICON Selected by Pfizer as a Global Strategic Partner for Clinical Research and Development
ICON Forms Strategic Alliance With Boston Clinical Research Institute Read more about ICON Forms Strategic Alliance With Boston Clinical Research Institute
